biotech · Alzheimer Disease · Major Depressive Disorder · CGTX
Cognition Therapeutics
COGNITION THERAPEUTICS INC
Cognition Therapeutics clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2500 Westchester Ave, Purchase, New York 10577, US
- Founded
- 2007
- Employees
- 32
- Programs
- 33
- Drugs
- 26
- Patents
- 12
Cognition Therapeutics projects
33 ClinicalTrials.gov programs sponsored by Cognition Therapeutics.
Cognition Therapeutics has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Treatment Resistant Psychosis
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Psychosis
1 trial -
Vortioxetine
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
Active Comparator CT1812
COGNITION THERAPEUTICS INC
Age-Related Macular Degeneration
1 trial -
Active Treatment- CT1812 100 mg
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Autobiographical Memory Flexibility (MemFlex) training
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
C105
COGNITION THERAPEUTICS INC
Cognition Disorders
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Early Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Dementia With Lewy Bodies
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Mild to Moderate Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer Disease
3 trials -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer's Disease
1 trial -
Dexmedetomidine
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Memory Flexibility Training
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
Oxytocin nasal spray
COGNITION THERAPEUTICS INC
Oxidative Stress
1 trial -
Oxytocin nasal spray
COGNITION THERAPEUTICS INC
Cold Exposure
1 trial -
Psilocybin
COGNITION THERAPEUTICS INC
Treatment Resistant Depression
1 trial -
The Modular Protocol for Mental Health
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
UCAB-CT-05
COGNITION THERAPEUTICS INC
Primary biliary cholangitis (PBC)
1 trial -
Vortioxetine
COGNITION THERAPEUTICS INC
Post-COVID-19 Condition
1 trial -
golexanolone
COGNITION THERAPEUTICS INC
Primary Biliary Cholangitis (PBC)
1 trial -
300 mg [C14] CT1812
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Healthy Volunteers
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Cognitive Impairment
1 trial -
Itraconazole
COGNITION THERAPEUTICS INC
Drug Interaction
1 trial -
24/7 EEG™ SubQ
COGNITION THERAPEUTICS INC
Sleep
1 trial -
Beverage powder fortified with micronutrients and Bacopa monnieri extract
COGNITION THERAPEUTICS INC
Cognition
1 trial -
Citalopram
COGNITION THERAPEUTICS INC
Antidepressive Agents, Second-Generation
1 trial -
Device measurements
COGNITION THERAPEUTICS INC
Healthy
1 trial -
Device measurements during overnight sleep and morning wake
COGNITION THERAPEUTICS INC
Healthy
1 trial -
Ketone ester
COGNITION THERAPEUTICS INC
Hypoxia
2 trials -
Nitrate enriched beetroot juice
COGNITION THERAPEUTICS INC
Aging
1 trial -
Overnight polysomnography
COGNITION THERAPEUTICS INC
Alzheimer Disease, Early Onset
1 trial
Frequently asked questions
How many clinical projects does Cognition Therapeutics have?
33 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.